Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5666316 | 0.87 | TSHR (0.48) | DRD2DRD4ALDH1A1GAADRD3 | |
| SCHEMBL9283305 | 0.84 | OPRD1 (0.50) | DRD2DRD4DRD3HTR3EHTR3B | |
| SCHEMBL5563304 | 0.84 | ALDH1A1 (0.46) | DRD2DRD4ALDH1A1ADRB1KDM4E | |
| SCHEMBL15545669 | 0.80 | HTR6 (0.44) | KMT2AADRB1HTR6 | |
| SCHEMBL112024 | 0.79 | ADRB1 (0.55) | DRD2MEN1KMT2ADRD3HTR3E | |
| SCHEMBL1742847 | 0.79 | ADRB1 (0.51) | DRD2GAADRD3HTR3EHTR3B | |
| SCHEMBL5564533 | 0.78 | BACE1 (0.44) | HTR3EHTR3BADRB1HTR3AHTR6 | |
| SCHEMBL8623037 | 0.78 | BACE1 (0.51) | DRD2ALDH1A1DRD3HTR3EHTR3B | |
| SCHEMBL16230836 | 0.76 | PRMT5 (0.44) | ALDH1A1ADRB1HTR6KDM4EHPGD | |
| SCHEMBL19667087 | 0.76 | NPC1 (0.51) | MAPK1DRD2DRD4ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884107-B2 | Human Double Minute 2 (HDM2) protein inhibitors; anticancer agents | MERCK (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884107-B2 | Human Double Minute 2 (HDM2) protein inhibitors; anticancer agents | MERCK (US) | 2011-02-08 | — | — | US | disclosed |
| WO-2008005268-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | SCHERING CORPORATION (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| EP-1603912-B1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS CH (CH) | 2007-07-18 | — | — | EP | disclosed |
| US-20060241123-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2006-10-26 | — | — | US | disclosed |
| EP-1603912-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004083209-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | TP53, MDM2, TP53BP1 | MAPK1 2877/4885DRD2 3748/4885DRD4 3717/4885 |
| US-20060241123-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | MAPK1 2677/4885DRD2 134/4885DRD4 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.